Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Journal article
Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928
-
Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models
Journal article
Rodriguez-Berriguete G. et al, (2023), Clinical Cancer Research
-
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
Journal article
Johanssen T. et al, (2023), Frontiers in Oncology, 12
-
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk.
Journal article
Rottner AK. et al, (2022), Nature genetics
-
Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors
Preprint
Wan X. et al, (2022)